Modifying therapeutic DNA aptamers to keep them in the bloodstream longer

November 29, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

Designing new therapeutic DNA aptamers with diverse side chains can improve their ability to interact with targets, and a new study describes characteristics of these side chains that may determine how long the aptamers remain in the bloodstream. Improving the pharmacokinetic properties of therapeutic aptamers is an important aspect of optimizing their drug-like properties, as discussed in the study published in Nucleic Acid Therapeutics.

In the article entitled "Pharmacokinetic Properties of DNA Aptamers with Base Modifications," Nebojsa Janjic, SomaLogic (Boulder, CO) and coauthors from SomaLogic and Otsuka Pharmaceutical (Tokushima, Japan), describe what effect the lengths of sequences have on plasma resident time. The researchers also demonstrate the importance of the hydrophobicity of the side chains on their rate of clearance from the bloodstream. The findings can serve as a guide for designing new aptamers with side chains that enhance their diversity.

"This elegant study demonstrates how nucleotide modifications can mitigate against nuclease degradation of aptamers, as vital a concern as is delivery for successful in vivo therapeutic or diagnostic applications," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Explore further: RNA aptamers targeted to plasminogen activator inhibitor

More information: Shashi Gupta et al, Pharmacokinetic Properties of DNA Aptamers with Base Modifications, Nucleic Acid Therapeutics (2017). DOI: 10.1089/nat.2017.0683

Related Stories

RNA aptamers targeted to plasminogen activator inhibitor

June 19, 2014
Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. ...

A natural sugar delivers DNA aptamer drug inside tumor cells

January 27, 2014
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own. Effective delivery of DNA aptamers ...

Medicine scholars develop innovative targeted delivery system for treating osteosarcoma

November 10, 2017
Chinese Medicine scholars at Hong Kong Baptist University (HKBU) have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS). Their research ...

Recommended for you

Fetal gene therapy prevents fatal neurodegenerative disease

July 16, 2018
A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women's and Children's Hospital and National University Health System ...

New study finds that fat consumption is the only cause of weight gain

July 13, 2018
Scientists from the University of Aberdeen and the Chinese Academy of Sciences have undertaken the largest study of its kind looking at what components of diet—fat, carbohydrates or protein—caused mice to gain weight.

Basic research in fruit flies leads to potential drug for diseases afflicting millions

July 13, 2018
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide. They are among the "neglected tropical diseases" for which better treatments are desperately ...

Light based cochlear implant restores hearing in gerbils

July 12, 2018
A team of researchers with members from a variety of institutions across Germany has developed a new type of cochlear implant—one based on light. In their paper published in the journal Science Translational Medicine, the ...

Researchers discover gene that controls bone-to-fat ratio in bone marrow

July 12, 2018
In an unexpected discovery, UCLA researchers have found that a gene previously known to control human metabolism also controls the equilibrium of bone and fat in bone marrow as well as how an adult stem cell expresses its ...

Intensive care patients' muscles unable to use fats for energy

July 12, 2018
The muscles of people in intensive care are less able to use fats for energy, contributing to extensive loss of muscle mass, finds a new study co-led by UCL, King's College London and Guy's and St Thomas' NHS Foundation Trust.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.